PolyPid Ltd. is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).
Company profile
Ticker
PYPD
Exchange
Website
CEO
Amir Weisberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • 3M • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
SEC CIK
PYPD stock data
Latest filings (excl ownership)
6-K
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
8 Feb 23
6-K
PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site
24 Jan 23
6-K
D-PLEX100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care
3 Jan 23
6-K
Meeting Scheduled for January 2023
12 Dec 22
6-K
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
9 Dec 22
6-K
PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results
9 Nov 22
6-K
PolyPid Announces Cost Reduction Plan
20 Oct 22
6-K
Report of Foreign Private Issuer
28 Sep 22
6-K
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
2 Sep 22
6-K
Report of Foreign Private Issuer
10 Aug 22
Transcripts
PYPD
Earnings call transcript
2022 Q4
8 Feb 23
PYPD
Earnings call transcript
2022 Q2
11 Aug 22
PYPD
Earnings call transcript
2022 Q1
11 May 22
PYPD
Earnings call transcript
2021 Q4
9 Feb 22
PYPD
Earnings call transcript
2021 Q2
11 Aug 21
PYPD
Earnings call transcript
2021 Q1
12 May 21
PYPD
Earnings call transcript
2020 Q4
10 Feb 21
PYPD
Earnings call transcript
2020 Q3
11 Nov 20
Financial summary
| Quarter (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
Institutional ownership, Q2 2022
21.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 29 |
| Opened positions | 2 |
| Closed positions | 2 |
| Increased positions | 5 |
| Reduced positions | 11 |
| 13F shares | Current |
|---|---|
| Total value | 20.23 mm |
| Total shares | 4.07 mm |
| Total puts | 21.20 k |
| Total calls | 132.70 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Aurum Ventures M.K.I. | 1.89 mm | $8.93 mm |
| Gabriel Capital Management | 1.11 mm | $6.36 mm |
| UBS UBS Group AG - Registered Shares | 279.38 k | $1.30 mm |
| Silverarc Capital Management | 161.57 k | $750.00 k |
| Alliancebernstein | 114.99 k | $534.00 k |
| MS Morgan Stanley | 102.75 k | $477.00 k |
| Victory Capital Management | 95.76 k | $444.00 k |
| Raymond James Financial Services Advisors | 53.26 k | $247.00 k |
| JFG Wealth Management | 39.06 k | $181.00 k |
| Meitav Dash Investments | 31.50 k | $145.00 k |
News
PolyPid Q4 EPS $(0.32) Versus $(0.72) Prior Year
8 Feb 23
Earnings Scheduled For February 8, 2023
8 Feb 23
PolyPid Earnings Preview
7 Feb 23
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
25 Jan 23
Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
25 Jan 23
Press releases
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
8 Feb 23
Thinking about buying stock in Grom Social Enterprises, Intelligent Bio Solutions, Polypid, CymaBay Therapeutics, or Draganfly?
24 Jan 23
PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
24 Jan 23
PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
3 Jan 23
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
12 Dec 22